PL3999180T3 - Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu - Google Patents

Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu

Info

Publication number
PL3999180T3
PL3999180T3 PL20753562.6T PL20753562T PL3999180T3 PL 3999180 T3 PL3999180 T3 PL 3999180T3 PL 20753562 T PL20753562 T PL 20753562T PL 3999180 T3 PL3999180 T3 PL 3999180T3
Authority
PL
Poland
Prior art keywords
ylo
ilo
inden
oxadiazol
pyrazolo
Prior art date
Application number
PL20753562.6T
Other languages
English (en)
Polish (pl)
Inventor
Norma TOM
Matthew PFEIFFER
Denise Andersen
Qi Gao
Original Assignee
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3999180(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics, Inc. filed Critical Cytokinetics, Inc.
Publication of PL3999180T3 publication Critical patent/PL3999180T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL20753562.6T 2019-07-17 2020-07-16 Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu PL3999180T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
PL3999180T3 true PL3999180T3 (pl) 2024-09-23

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20753562.6T PL3999180T3 (pl) 2019-07-17 2020-07-16 Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu

Country Status (25)

Country Link
US (1) US20220315571A1 (https=)
EP (2) EP3999180B1 (https=)
JP (2) JP7624431B2 (https=)
KR (1) KR20220084008A (https=)
CN (3) CN114555590B (https=)
AU (1) AU2020313965A1 (https=)
BR (1) BR112022000494A2 (https=)
CA (1) CA3144975A1 (https=)
CL (1) CL2022000054A1 (https=)
DK (1) DK3999180T3 (https=)
ES (1) ES2980885T3 (https=)
FI (1) FI3999180T3 (https=)
HR (1) HRP20240713T1 (https=)
HU (1) HUE066891T2 (https=)
IL (1) IL289875A (https=)
LT (1) LT3999180T (https=)
MX (1) MX2022000504A (https=)
PH (1) PH12022550123A1 (https=)
PL (1) PL3999180T3 (https=)
PT (1) PT3999180T (https=)
RS (1) RS65611B1 (https=)
SI (1) SI3999180T1 (https=)
SM (1) SMT202400224T1 (https=)
TW (1) TWI865562B (https=)
WO (1) WO2021011807A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
MX2024001294A (es) 2021-08-03 2024-02-13 Cytokinetics Inc Proceso para la preparacion de aficamten.
WO2024020468A1 (en) 2022-07-20 2024-01-25 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
EP4565230A1 (en) 2022-08-04 2025-06-11 Cytokinetics, Inc. Methods for treating obstructive hypertrophic cardiomyopathy
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
US20250295639A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
MX2024001294A (es) * 2021-08-03 2024-02-13 Cytokinetics Inc Proceso para la preparacion de aficamten.

Also Published As

Publication number Publication date
CA3144975A1 (en) 2021-01-21
IL289875A (en) 2022-03-01
CN118908951A (zh) 2024-11-08
EP3999180B1 (en) 2024-05-08
NZ784930A (en) 2025-03-28
SMT202400224T1 (it) 2024-07-09
JP2022540668A (ja) 2022-09-16
DK3999180T3 (da) 2024-05-21
HRP20240713T1 (hr) 2024-09-13
JP2025061484A (ja) 2025-04-10
JP7624431B2 (ja) 2025-01-30
EP4487911A1 (en) 2025-01-08
ES2980885T3 (es) 2024-10-03
AU2020313965A1 (en) 2022-03-03
LT3999180T (lt) 2024-08-26
US20220315571A1 (en) 2022-10-06
WO2021011807A1 (en) 2021-01-21
SI3999180T1 (sl) 2024-07-31
RS65611B1 (sr) 2024-07-31
HUE066891T2 (hu) 2024-09-28
KR20220084008A (ko) 2022-06-21
FI3999180T3 (fi) 2024-06-18
TWI865562B (zh) 2024-12-11
CN114555590B (zh) 2024-09-10
CN114555590A (zh) 2022-05-27
CL2022000054A1 (es) 2022-10-07
TW202116763A (zh) 2021-05-01
PH12022550123A1 (en) 2022-12-19
EP3999180A1 (en) 2022-05-25
JP7755090B2 (ja) 2025-10-15
BR112022000494A2 (pt) 2022-03-03
PT3999180T (pt) 2024-06-25
MX2022000504A (es) 2022-02-10
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
PL3999180T3 (pl) Polimorfy (r)-n-(5-(5-etylo-1,2,4-oksadiazol-3-ilo)-2,3-dihydro-1h-inden-1-ylo)-1-metylo-1h-pirazolo-4-karboksyamidu
MA55131A (fr) Nouveaux composés hétérocycliques
EP3941898C0 (en) FUNGICIDAL COMPOUNDS
EP4061364A4 (en) HETEROARYL COMPOUNDS
IL291384A (en) Process for preparing 5-(fluoro-4-imino-3-methyl)-1-tosyl-3,4 dihydropyrimidine -(1h)-one
LT4021901T (lt) Pakeistieji piridopirimidinonilo junginiai, naudotini kaip t ląstelių aktyvatoriai
LT3814348T (lt) Pakeistieji naftiridinono junginiai, naudotini kaip t ląstelių aktyvatoriai
MA56115A (fr) Composés de pyrrolidine
PT3433232T (pt) Novo sal de adição de ácido de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
EP3551176A4 (en) Antidiabetic heterocyclic compounds
EP3924358A4 (en) Macrocyclic compounds
DK3402784T3 (da) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
MA53547A (fr) Composés de 2,6-diamino pyridine
MA53479A (fr) Composés hétérocycliques en tant q'inibiteurs de vanin
DK3418275T3 (da) Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer
EP4077318A4 (en) Compounds
DK3722284T3 (da) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4,5]-decan-derivater
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
IL289881A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide
IL284610A (en) Communicating print component
JP1641212S (ja) プリンター
EP3693360C0 (en) Heterocyclic compounds
EP4006037A4 (en) HETEROCYCLIC COMPOUND
JP1668564S (ja) テープ印字機